2006
DOI: 10.18388/abp.2006_3291
|View full text |Cite
|
Sign up to set email alerts
|

Structural aspects of L-asparaginases, their friends and relations.

Abstract: Enzymes capable of converting l-asparagine to l-aspartate can be classified as bacterial-type or plant-type l-asparaginases. Bacterial-type l-asparaginases are further divided into subtypes I and II, defined by their intra-/extra-cellular localization, substrate affinity, and oligomeric form. Planttype l-asparaginases are evolutionarily and structurally distinct from the bacterial-type enzymes. They function as potassium-dependent or -independent Ntn-hydrolases, similar to the well characterized aspartylglucos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

2
75
0
3

Year Published

2011
2011
2021
2021

Publication Types

Select...
6
3

Relationship

2
7

Authors

Journals

citations
Cited by 116 publications
(80 citation statements)
references
References 71 publications
2
75
0
3
Order By: Relevance
“…The 16S rRNA sequencing was found to be a phylogenetic tool also useful for bacterial detection and identification, it can better identify poorly described strains (Matsumoto and Sugano Fortunately, our test isolate that used in the present study could produce l-asparaginase extracellularly (Type II l-asparaginase) at a level 470% more than its intracellular level. Bacterial l-asparaginases are defined by their intra or extra cellular localization (Michalska and Jaskolski 2006). Type I (cytosolic) binds to l-asparagine with low affinity, in contrast the extracellular type II (periplasmic) has a strong binding capacity and it has a characteristic oligomeric form.…”
Section: Discussionmentioning
confidence: 99%
“…The 16S rRNA sequencing was found to be a phylogenetic tool also useful for bacterial detection and identification, it can better identify poorly described strains (Matsumoto and Sugano Fortunately, our test isolate that used in the present study could produce l-asparaginase extracellularly (Type II l-asparaginase) at a level 470% more than its intracellular level. Bacterial l-asparaginases are defined by their intra or extra cellular localization (Michalska and Jaskolski 2006). Type I (cytosolic) binds to l-asparagine with low affinity, in contrast the extracellular type II (periplasmic) has a strong binding capacity and it has a characteristic oligomeric form.…”
Section: Discussionmentioning
confidence: 99%
“…Another functional group in the active site that can be ionized is the aamino group of the Thr-196 nucleophile. This group needs to be unprotonated in Ntn hydrolases in order to activate the side-chain hydroxyl for nucleophilic attack on the amide group of the substrate [3]. The value of pK 1 is most likely to reflect the ionization of this group.…”
Section: Discussionmentioning
confidence: 99%
“…L-Asparaginase is the enzyme responsible for this hydrolytic reaction. L-Asparaginases are present in most organisms, and have been classified into two major types, the bacterial-(also called type I and II) and plant-type (or type III) asparaginases [3]. The bacterial type II enzymes, with high L-asparagine affinity, are useful for treating acute lymphoblastic leukemia [4].…”
Section: Introductionmentioning
confidence: 99%
“…In E. coli , two evolutionarily related l ‐asparaginases are present: the periplasmic, highly active enzyme ( K M = 10–12 μ m ) with potent cytotoxic properties, and its less active but allosteric cytosolic homolog ( K 0.5 = 1.0 m m ) lacking any antileukemic properties . The two enzymes have been classified as bacterial‐type l ‐asparaginases type I (the cytoplasmic protein, EcAI) and type II (the periplasmic protein, EcAII) to differentiate them from each other as well as from another group of evolutionarily unrelated l ‐asparaginases, sometimes called plant‐type l ‐asparaginases . The l ‐asparaginase from E. chrysanthemi and EcAII were soon introduced into clinical practice as very effective agents for the treatment of childhood acute lymphoblastic leukemia (ALL) and became standard components of protocols in ALL therapy .…”
Section: Introductionmentioning
confidence: 99%